EXCLUSIVE: Telo Genomics' Smoldering Multiple Myeloma Prognostic Test Predicts Risk Of Disease Progression, Study Shows
EXCLUSIVE: Telo Genomics' Smoldering Multiple Myeloma Prognostic Test Predicts Risk Of Disease Progression, Study Shows
On Thursday, Telo Genomics Corp (OTC:TDSGF) announced that the manuscript "Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myeloma" was accepted for publication in the American Journal of Hematology.
Telo Genomics Corp (場外交易:TDSGF)週四宣佈，手稿“三維端粒結構預測隱性多發性骨髓瘤惡化風險”被美國血液學雜誌接受發表。
The published study included a total of 168 smoldering multiple myeloma patients.
該發表的研究包括總共168名隱性多發性骨髓瘤患者。
The article describes the results of Telo's prognostic test for smoldering multiple myeloma (TeloViewSMM).
文章描述了Telo針對隱性多發性骨髓瘤（TeloViewSMM）的預測性檢測結果。
The results described in the publication demonstrated superior performance characteristics compared to other oncology prognostic tests or scoring systems in smoldering multiple myeloma (SMM), particularly for SMM but also across other cancers.
所述出版物中描述的結果表明，與其他癌症預後測試或評分系統相比，TeloViewSMM具有優越的表現特徵，特別是針對隱性多發性骨髓瘤(SMM)，但也適用於其他癌症。
In the published independent validation included in the study, the TeloView test scored an 85% positive predictive value (accuracy in identifying high-risk patients) and a 73% negative predictive value (accuracy in identifying stable patients), with associated sensitivity & specificity of 83% & 76%, respectively.
在所述研究中包括的獨立驗證後的出版物中，TeloView檢測得分爲85%的陽性預測值(識別高風險患者的準確率)和73%的陰性預測值(確定穩定患者的準確率)，具有相關的靈敏度和特異性分別爲83%和76%。
The test stratifies patients flagged with the elevated M-protein biomarker between high-risk patients who will progress to the full stage of myeloma disease and low-risk patients and confirms the stability of the disease in these patients.
該檢測將被標記爲存在高M蛋白生物標記的患者分爲高風險患者和低風險患者，並確認這些患者疾病的穩定性。
Critically, TeloViewSMM can be used as a non-invasive liquid biopsy and can be performed using a simple blood draw.
關鍵是，TeloViewSMM可作爲非侵入性液體活檢，並可使用簡單的血液採集進行。
According to recent demographic studies, SMM prevalence is estimated to be 0.5% of the population over 40 years old, suggesting that TeloViewSMM's total addressable market is approximately 500,000 tests and greater annually.
根據最近的人口統計學研究，隱性多發性骨髓瘤的患病率估計爲40歲以上人口的0.5％，這意味着TeloViewSMM的總可尋址市場約爲每年50萬次以上。
Earlier this month, Telo Genomics announced a non-brokered private placement of units at $0.25 per unit for gross proceeds of $2 million.
本月早些時候，Telo Genomics宣佈進行定向增發，每股價格爲0.25美元，募資200萬美元。
Price Action: TDSGF shares closed at $0.13 on Wednesday.
價格走勢：TDSGF股價週三收盤於0.13美元。
譯文內容由第三人軟體翻譯。